Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other best stocks that stole the show last week.

Recursion Pharmaceuticals jumped by 31.3 percent week-on-week following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity.

According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1.

“Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,” said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan.

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

“By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,” she added.

Overall, RXRX ranks 6th on our list of best stocks that stole the show last week. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.